|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Net Sales | |||||
| Cost of products sold, excluding intangible asset amortization | |||||
| Intangible asset amortization | |||||
| Research and development | |||||
| Selling, general and administrative | |||||
| Goodwill and intangible asset impairment | |||||
| Restructuring and other cost reduction initiatives | |||||
| Quality remediation | |||||
| Acquisition, integration, divestiture and related | |||||
| Operating expenses | |||||
| Operating Profit | |||||
| Other income (expense), net | |||||
| Interest expense, net | |||||
| Earnings before income taxes | |||||
| Provision for income taxes | |||||
| Net Earnings (Loss) | |||||
| Net Earnings | |||||
| Less: Net (loss) earnings attributable to noncontrolling interest | |||||
| Net Earnings from Continuing Operations of Zimmer Biomet Holdings, Inc. | |||||
| Loss from Discontinued Operations, Net of Tax | |||||
| Net Earnings of Zimmer Biomet Holdings, Inc. | |||||
| Earnings from Continuing Operations | |||||
| Earnings Per Common Share | |||||
| Basic | |||||
| Earnings from Continuing Operations | |||||
| Diluted | |||||
| Weighted Average Common Shares Outstanding | |||||
| Basic | |||||
| Diluted | |||||
Loading...